GlassScriptPhysician profile
Sherif M Ibrahim
NPI 1467416776
$915.07
in general payments reported to CMS, 2019-2025
16 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.98 · 2020: $35.35 · 2021: $57.01 · 2022: $235 · 2023: $198 · 2024: $117 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.57 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $222.32 | 2020-2025 | Jynarque, Voyxact |
| E.R. Squibb & Sons, L.L.C. | $129.05 | 2022-2025 | Opdivo |
| Mallinckrodt Hospital Products INC. | $113.51 | 2021-2025 | Acthar, Terlivaz |
| Corcept Therapeutics | $96.92 | 2023 | Korlym |
| Aurinia Pharma U.S., INC. | $58.72 | 2022 | |
| Fresenius USA Marketing, INC. | $50.70 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $45.57 | 2023 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $43.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $33.97 | 2022 | |
| Glaxosmithkline, LLC. | $23.93 | 2024 | Trelegy Ellipta |
| Shire North American Group INC | $18.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Astellas Pharma US INC | $16.37 | 2025 | Padcev |
| Daiichi Sankyo INC. | $15.63 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.